Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(l → 4)-D-β-glucan
Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(l → 4)-D-β-glucan
复制标题
DOI：
10.1016/j.leukres.2004.10.008
复制
发表时间：
2005-06-01
影响因子：
2.7
通讯作者：
Cheung, NKV
中科院分区：
文献类型：
--
作者：
Modak, S;Koehne, G;Cheung, NKV
通过激活补体，抗肿瘤单克隆抗体在肿瘤细胞表面包裹iC3b。β -葡聚糖，天然存在的葡萄糖聚合物，结合到白细胞受体CR3的凝集素结构域，使其与iC3b结合，并触发iC3b包被肿瘤细胞的细胞毒性。我们研究了补体活化抗体利妥昔单抗与大麦来源的（1 -> - 3），(1 -> - 4)- β -d -葡聚糖（BG）联合用于SCID小鼠CD-20阳性淋巴瘤异种移植。在静脉注射利妥昔单抗和口服BG联合治疗的小鼠中，已建立的皮下非霍奇金淋巴瘤（NHL） （Daudi和ebv衍生的B-NHL）或霍奇金病（Hs445和RPM16666）的生长明显抑制。与单独使用利妥昔单抗或BG治疗的小鼠相比。与其他治疗组相比，联合组弥散性淋巴瘤小鼠的生存率显著提高。未观察到临床毒性。该组合的治疗效果和无毒性支持对其临床应用的进一步研究。(c) 2004 Elsevier Ltd.版权所有。
By activating complement, antitumor monoclonal antibodies coat tumor cells with iC3b. beta-gluans, naturally occurring glucose polymers, bind to the lectin domain Of the leukocyte receptor CR3, prime it for binding to iC3b, and trigger cytotoxicity of iC3b-coated tumor cells. We Studied the combination of the complement-activating antibody rituximab with barley-derived (1 -> 3),(1 -> 4)-beta-D-glucan (BG) against CD-20 positive lymphoma xenografts in SCID mice. Growth of established subcutaneous non-Hodgkin's lymphoma (NHL) (Daudi and EBV-derived B-NHL) or Hodgkin's disease (Hs445 and RPM16666) was significantly Suppressed in mice treated with a combination of intravenous rituximab and oral BG. when compared to mice treated with rituximab or BG alone. Survival of mice with disseminated lymphoma was significantly increased in the combination group as compared to other treatment groups. No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination Supports further investigation into its clinical utility. (c) 2004 Elsevier Ltd. All rights reserved.